ZENAS DINER CATERINGBusiness Directories,Company Directories

Company Name: Corporate Name:	ZENAS DINER & CATERING
Company Title:
Company Description:
Keywords to Search:
Company Address:	2703 Eglinton Ave E,SCARBOROUGH,ON,Canada
ZIP Code: Postal Code:	M1K2S2
Telephone Number:	4162698073
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	581208
USA SIC Description:	Restaurants
Number of Employees:	1 to 4
Sales Amount:	Less than $500,000
Credit History: Credit Report:	Very Good
Contact Person:	Fred Akeem
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
ZERALD COMMUNICATIONS
ZENITH COMPUTER SYSTEMS
ZENAS DINER

Next company profile:
ZEN JAPANESE RESTAURANT
ZEN COMPUTER CONSULTANTS
ZELLERS SELECT PHARMACY

Company News:

Home - Zenas BioPharma
Leading With Intention Our commitment to being a leader in the development and commercialization of therapies for autoimmune diseases is clear With our exceptional team, we believe we can Explore the Zenas Experience
Who We Are - Zenas BioPharma
Zenas BioPharma is committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases so that patients with autoimmune diseases can reimagine life
News - Zenas BioPharma
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Pipeline - Zenas BioPharma
Zenas is committed to being a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases This begins with obexelimab, a potential franchise within a molecule, targeting B cell mediated autoimmune diseases
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to . . .
Zenas is developing its lead product candidate ZB001, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb), for the potential treatment of patients in China with thyroid eye disease (TED)
Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of . . .
WALTHAM, Mass, November 7, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from . . .
“In Zenas BioPharma, we have found a partner committed to broadly and aggressively developing therapeutics like obexelimab for patients with autoimmune diseases, enabling Xencor’s continued focus on the growing opportunities provided by our XmAb bispecific antibody and cytokine pipeline ”
Job Openings - Zenas BioPharma
Learn more about our open positions and how you can become part of the Zenas experience Together, we can reimage life for patients with autoimmune diseases worldwide
News Releases | Zenas BioPharma, Inc
WALTHAM, Mass , Jan 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced